KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Tax Provisions: 2017-2025

Historic Tax Provisions for Sarepta Therapeutics (SRPT) over the last 8 years, with Jun 2025 value amounting to $64.0 million.

  • Sarepta Therapeutics' Tax Provisions rose 799.76% to $64.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $84.5 million, marking a year-over-year increase of 459.95%. This contributed to the annual value of $25.8 million for FY2024, which is 60.71% up from last year.
  • As of Q2 2025, Sarepta Therapeutics' Tax Provisions stood at $64.0 million, which was up 394.75% from $12.9 million recorded in Q4 2024.
  • Sarepta Therapeutics' Tax Provisions' 5-year high stood at $64.0 million during Q2 2025, with a 5-year trough of -$5.2 million in Q4 2023.
  • Over the past 3 years, Sarepta Therapeutics' median Tax Provisions value was $7.1 million (recorded in 2024), while the average stood at $11.8 million.
  • In the last 5 years, Sarepta Therapeutics' Tax Provisions slumped by 1,870.00% in 2021 and then surged by 9,193.48% in 2022.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Tax Provisions stood at $92,000 in 2021, then surged by 9,193.48% to $8.6 million in 2022, then tumbled by 160.30% to -$5.2 million in 2023, then soared by 351.03% to $12.9 million in 2024, then spiked by 799.76% to $64.0 million in 2025.
  • Its last three reported values are $64.0 million in Q2 2025, $12.9 million for Q4 2024, and $400,000 during Q3 2024.